Targeted Combination Therapy for Advanced Solid Tumors
Name of the Trial
Why Is This Trial Important?
Solid tumors depend upon new blood vessel formation - a process known as angiogenesis - to obtain oxygen and nutrients for continued growth. A variety of antiangiogenic drugs targeting this "Achilles' heel" has been under development for several years.
An angiogenesis inhibitor called bevacizumab (Avastin) received FDA approval in 2004 for the treatment of advanced colorectal cancer. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein produced by many types of cancer cells that stimulates new blood vessel growth in tumors.
In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Sorafenib also inhibits angiogenesis, but it does so by blocking the activity of proteins that are activated by VEGF (namely, VEGF receptor proteins). Importantly, the antitumor effects of sorafenib extend beyond VEGF receptor protein inhibition to include inhibition of other proteins that may be involved in cancer cell proliferation and tumor growth.
"We hope that the antitumor effects of these two targeted agents will prove mutually reinforcing when given in combination," said Dr. Kohn.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.